Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Hydroxyprogesterone heptanoate

From Wikipedia, the free encyclopedia
Chemical compound
Not to be confused with17α-Hydroxyprogesterone,Hydroxyprogesterone acetate, orHydroxyprogesterone caproate.
Pharmaceutical compound
Hydroxyprogesterone heptanoate
Clinical data
Trade namesH.O.P, Hydroxyprogesterone, Lutogil A.P., Lutogyl A.P., others
Other namesOHPH; Hydroxyprogesterone enanthate; OHPE; 17α-Hydroxyprogesterone heptanoate; 17α-Hydroxyprogesterone heptylate; 17α-Hydroxypregn-4-ene-3,20-dione 17α-heptanoate; 17α-Heptyloylpregn-4-ene-3,20-dione
Routes of
administration
Intramuscular injection
Drug classProgestogen;Progestin;Progestogen ester
ATC code
Identifiers
  • [(8R,9S,10R,13S,14S,17R)-17-Acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] heptanoate
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
ECHA InfoCard100.022.724Edit this at Wikidata
Chemical and physical data
FormulaC28H42O4
Molar mass442.640 g·mol−1
3D model (JSmol)
  • CCCCCCC(=O)OC1(CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C)C(=O)C
  • InChI=1S/C28H42O4/c1-5-6-7-8-9-25(31)32-28(19(2)29)17-14-24-22-11-10-20-18-21(30)12-15-26(20,3)23(22)13-16-27(24,28)4/h18,22-24H,5-17H2,1-4H3/t22-,23+,24+,26+,27+,28+/m1/s1
  • Key:NKJYZYWCGKSMSV-BDPSOKNUSA-N

Hydroxyprogesterone heptanoate (OHPH), also known ashydroxyprogesterone enanthate (OHPE) and sold under the brand namesH.O.P.,Lutogil A.P., andLutogyl A.P. among others, is aprogestin medication used forprogestogenic indications.[1][2][3][4] It has been formulated both alone and in together withestrogens,androgens/anabolic steroids, and otherprogestogens in severalcombination preparations (brand namesTocogestan,Trioestrine Retard, andTriormon Depositum).[4][5][6][7][8][9][10] OHPH is given byinjection into muscle at regular intervals.[11][9]

OHPH is a progestin, or asyntheticprogestogen, and hence is anagonist of theprogesterone receptor, thebiological target of progestogens likeprogesterone.[12][13][14] It appears to have similarpharmacology to that of the closely related medicationhydroxyprogesterone caproate (OHPC).[15][16][17]

OHPH was first described by 1954[16] and was introduced for medical use by 1957.[6] It has been used clinically inFrance andMonaco in the past but is no longer marketed.[2][3][4]

Medical uses

[edit]

OHPH is aprogestogen and was used in situations in which progestogens were indicated.[12][13][14]

Available forms

[edit]

OHPH was provided as a 125 mg/1 mLoil solution for use byintramuscular injection.[3][11] In addition to single-drug preparations, OHPH has also been used in a number of multi-drug formulations.[4][5][6][7][8][9][10] It was used inTocogestan, a combination of 50 mgprogesterone, 200 mg OHPH, and 250 mgα-tocopherol palmitate (vitamin E) inoil solution for use by intramuscular injection.[18][4][5] It was also used inTriormon Depositum (estradiol dibutyrate,testosterone caproate, and OHPH) andTrioestrine Retard (estradiol diundecylate,testosterone cyclohexylpropionate, and OHPH).[6][7] OHPH was a component of the experimental preparationTrophobolene (or Trophoboline), which also containedestrapronicate (estradiol nicotinate propionate) andnandrolone undecanoate, as well.[8][9][10]

Pharmacology

[edit]

Pharmacodynamics

[edit]

OHPH is a progestin, or asyntheticprogestogen, and hence is anagonist of theprogesterone receptor, thebiological target of progestogens likeprogesterone.[15][12][13][14] The progestogenic potency of OHPH in theuterus is equal to or greater than that ofprogesterone when administered bysubcutaneous injection in animals.[15][16][17] Its potency in animals likewise appears to be similar to that ofhydroxyprogesterone caproate.[15][16][17]

Pharmacokinetics

[edit]

OHPH shows a pronounceddepot effect when administered bysubcutaneous injection in animals, similarly to the closely related medicationhydroxyprogesterone caproate.[15][16] Theoral activity of OHPH in animals does not appear to have been assessed.[15]

Chemistry

[edit]
See also:List of progestogens,Progestogen ester, andList of progestogen esters

OHPH, also known as hydroxyprogesterone enanthate (OHPE),[19] as well as 17α-hydroxyprogesterone heptanoate or 17α-hydroxypregn-4-ene-3,20-dione 17α-heptanoate, is asyntheticpregnanesteroid and aderivative ofprogesterone and17α-hydroxyprogesterone.[1][2] It is aprogestogen ester; specifically, it is the C17αheptanoate (enanthate)ester of 17α-hydroxyprogesterone.[1][2]Analogues of OHPH include the more well-known medicationshydroxyprogesterone acetate andhydroxyprogesterone caproate (hydroxyprogesterone hexanoate).[1][2] The C3benzilic acidhydrazone of OHPH,hydroxyprogesterone heptanoate benzilic acid hydrazone (OHPHBH), is known and has been studied in animals.[20][21] In terms ofchemical structure, OHPH is very similar to hydroxyprogesterone caproate, differing from it only in having one additionalcarbon in itsfatty acidesterchain.[1][2]

History

[edit]

OHPH was first described, along withhydroxyprogesterone caproate andhydroxyprogesterone acetate, by Karl Junkmann ofSchering AG in 1954.[16][19] It was introduced for medical use by 1957.[6] OHPH was commercialized byRoussel andThéramex, and has been used clinically inFrance andMonaco but is no longer marketed.[2][3][4]

Society and culture

[edit]

Brand names

[edit]

OHPH has been marketed alone under a number of brand names including H.O.P, Hydroxyprogesterone, Lutogil A.P., and Lutogyl A.P.[1][2][3][4]

Availability

[edit]

OHPH was previously marketed inFrance andMonaco but is no longer available.[2][3][22]

See also

[edit]

References

[edit]
  1. ^abcdefElks J (14 November 2014).The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 665–.ISBN 978-1-4757-2085-3.
  2. ^abcdefghiIndex Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 532–.ISBN 978-3-88763-075-1.
  3. ^abcdefMuller NF, Dessing RP (19 June 1998).European Drug Index: European Drug Registrations (Fourth ed.). CRC Press. pp. 612–.ISBN 978-3-7692-2114-5.
  4. ^abcdefgKleemann A, Engel J (2001).Pharmaceutical Substances: Syntheses, Patents, Applications. Thieme. p. 1033.ISBN 978-3-13-558404-1.
  5. ^abcSasco AJ, Gendre I, Verbier-Naneix C, Soulier JL, Raffi F, Satgé D, Robert E (1998)."Neonatal neuroblastoma and in utero exposure to progestagens".International Journal of Risk and Safety in Medicine.11 (2):121–128.
  6. ^abcdeErmiglia G, Valli P (1957). "Triormon depositum in climacteric syndrome. Curves of excretion of catabolites and duration of the therapeutic effect".Quaderni Clin. Ostet. E Ginecol.12:284–93.Triormon depositum (estradiol dibutyrate 3, testosterone caprylate 50, and hydroxyprogesterone heptanoate 30 mg.), administered in castor oil-benzyl benzoate soln. or polyvinylpyrrolidone suspension to 21 women in climacteric, was followed by estradiol, pregnanediol, and 17-keto steroid urinary curves, most with a peak at the 4th day, and approaching starting values at the 8-10th day. The therapeutic efficacy of the drug was satisfactory.
  7. ^abcBordier P (1963). "Cure of fifteen osteoporosis cases by a delayed effect of hormonal association".Semaine des Hopitaux.39 (2):81–4.ISSN 0037-1777.The patients (females) received intramuscularly, every 10 days for 2-3 months, estradiol diundecyleate 2.25, testosterone cyclohexylpropionate 67.5, and hydroxyprogesterone heptylate 100 mg. ("trioestrine retard"). Their av. calcuria decreased 30.5% (0-69%) and asthenia, anorexia, and muscular activity improved.
  8. ^abcExcerpta medica. Section 8, Neurology and neurosurgery. 1981. p. 10.
  9. ^abcd"Nandarolone".Testosterone Congeners—Advances in Research and Application: 2013 Edition: ScholarlyBrief. ScholarlyEditions. 21 June 2013. pp. 137–.ISBN 978-1-4816-9288-5.
  10. ^abcFrigerio A (1981).Chromatography in Biochemistry, Medicine and Environmental Research: Proceedings of the ... International Symposium on Chromatography in Biochemistry, Medicine and Environmental Research. Elsevier Scientific Publishing Company. p. 99.ISBN 9780444420169.
  11. ^abKrówczyński L (1987).Extended Release Dosage Forms. CRC Press. p. 12.ISBN 978-0-8493-4307-0.Progestogens. [...] Hydroxyprogesterone heptanoate. Hydroxyprogesterone (Theramex). Oily solution for injection.
  12. ^abcSchindler AE (July 2014). "The "newer" progestogens and postmenopausal hormone therapy (HRT)".The Journal of Steroid Biochemistry and Molecular Biology.142:48–51.doi:10.1016/j.jsbmb.2013.12.003.PMID 24333799.S2CID 32126275.
  13. ^abcBińkowska M, Woroń J (June 2015)."Progestogens in menopausal hormone therapy".Przeglad Menopauzalny = Menopause Review.14 (2):134–143.doi:10.5114/pm.2015.52154.PMC 4498031.PMID 26327902.
  14. ^abcPosaci C, Smitz J, Camus M, Osmanagaoglu K, Devroey P (June 2000)."Progesterone for the luteal support of assisted reproductive technologies: clinical options".Human Reproduction.15 (suppl 1):129–148.doi:10.1093/humrep/15.suppl_1.129.PMID 10928425.
  15. ^abcdefNeumann F, Elger W, Salloch RR, Tube O, Neumann HF (1969). "Besonderheiten der Wirkungen der einzelnen Gestagene auf Morphologie und Funktion des Genitaltraktes bei Säugetieren" [Special features of the effects of the individual gestagens on the morphology and function of the genital tract in mammals].Die Gestagene [Progestogens]. Vol. 2. Springer-Verlag. pp. 50–131.ISBN 978-3-662-00826-3.
  16. ^abcdefJunkmann K (1954). "Über protrahiert wirksame Gestagene".Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie.223 (3).doi:10.1007/BF00246995.S2CID 33591186.
  17. ^abcJunkmann K (1959).Über Entwicklungen auf dem Gestagengebiet. 15. General Assembly of the Japan Medical Congress, Tokyo. Vol. 1. pp. 697–706.
  18. ^"Formulation".
  19. ^abBatres E, Gomez R, Rosenkranz G, Sondheimer F (1956). "Notes - Steroids. LXXVI. Synthesis of Long Chain Carboxylic Acid Esters of 17α-Hydroxyprogesterone".The Journal of Organic Chemistry.21 (2):240–241.doi:10.1021/jo01108a601.ISSN 0022-3263.
  20. ^Shipley EG (1962)."Anti-gonadotropic steroids, inhibition of ovulation and mating". In Dorfman RI (ed.).Methods in Hormone Research. Vol. 2. Elsevier. pp. 252–.ISBN 978-1-4832-7276-4.{{cite book}}:ISBN / Date incompatibility (help)
  21. ^Gleason CH, Parker JM (1959). "The duration of activity of the benziloyl hydrazones of testosterone-17-heptanoate, estrone-3-heptanoate and 17α-hydroxy-progesterone-17-heptanoate".Endocrinology.65 (3):508–511.doi:10.1210/endo-65-3-508.ISSN 0013-7227.PMID 13828402.
  22. ^"OHPH".micromedexsolutions.com.
Progestogens
(andprogestins)
PRTooltip Progesterone receptoragonists
Antiprogestogens
SPRMsTooltip Selective progesterone receptor modulators
PRTooltip Progesterone receptorantagonists
PRTooltip Progesterone receptor
Agonists
Mixed
(SPRMsTooltip Selective progesterone receptor modulators)
Antagonists
mPRTooltip Membrane progesterone receptor
(PAQRTooltip Progestin and adipoQ receptor)
Agonists
Antagonists
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hydroxyprogesterone_heptanoate&oldid=1227944153"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp